GMT EIGHT - Company

FOURTH PARADIGM (06682) and Huawei jointly release the SageOne IA integrated machine, providing a new generation of full-stack infrastructure.

Recently, FOURTH PARADIGM (06682) collaborated with Huawei Ascend AI to release a new upgraded SageOne IA integrated machine solution, supporting mainstream large models such as DeepSeek V3/R1, QWen2.5, and LLama3.3. Enterprises can flexibly switch between the full-blood version and multiple distilled models. The solution integrates intelligent computing power pooling technology (vGPU), a large model application development platform, and a ready-to-use AI application suite. It builds a complete self-owned technical system from bottom-level computing power to upper-level applications, providing a new generation of full-stack infrastructure for enterprise intelligent transformation. SageOne IA integrated machine has three core advantages: 1. Intelligent computing resource dynamic scheduling system Breaking the shackles of traditional physical architecture, adopting FOURTH PARADIGM's innovative vGPU resource pooling technology, achieving three major innovations: 1) Dynamic resource splitting: Supporting power pooling splitting, flexibly switching between different sizes of large models, increasing GPU utilization by more than 30%. 2) Intelligent task scheduling: Through storage sharing and computing optimization technology, single-machine multitasking processing efficiency is increased by 3 times, and inference performance is increased by 5-10 times. 3) Elastic expansion capability: With the increase in intelligent computing demand, seamless expansion can be achieved, and kilocalorie-level cluster management supports seamless expansion of business. 2. Enterprise-level large model development platform Building a development empowerment system covering the entire lifecycle of AI applications: 1) Model factory: Integrated with more than 150 mainstream large models, supporting rapid fine-tuning deployment. 2) Intelligent body framework: Providing visual workflow orchestration and automated document parsing tools. 3) Development efficiency improvement: Shortening application development cycle by 95% through the LLM Ops system, supporting weekly online launch. 3. Ready-to-use AI application matrix Pre-installed intelligent application suite covering core enterprise scenarios, including AIGC, intelligent office, digital employees, intelligent Q&A, AI local search, analysis decisions, large model development tools, model repositories, intelligent body agent platforms, DevOps, etc. The deep collaboration between FOURTH PARADIGM and Huawei Ascend AI marks a new stage in the "soft and hard coordination, scenario-driven" development of domestic AI infrastructure. We will continue to deepen the integration and innovation of large models with industry scenarios, helping enterprises achieve an exponential increase in AI value transformation efficiency.

14 min ago

Nearly ten thousand domestic GPUs! Lenovo (00992) Mu Xi DeepSeek all-in-one machine shipped over a thousand units in its first month on the market.

On March 7, 2025, during the peak of the national "Two Sessions", hot topics such as "Artificial Intelligence+" and "Intelligent Terminals" have attracted widespread attention, highlighting the high level of attention from the government and industry to AI technology. Since the joint release of the first domestic DeepSeek all-in-one machine solution by LENOVO GROUP (00992) and the leading domestic GPU company Muxi Corporation on February 5, 2025, this software-hardware AI product has quickly become the focus of the industry. As of today, the cumulative shipments of this solution have exceeded a thousand units, equipped with nearly ten thousand Muxi domestic GPU cards, covering more than ten core industries such as medical, education, and manufacturing, marking an important milestone in the landing of the domestic AI industry. The landing of large-scale models in various industries accelerates, and the demand for AI all-in-one machines surges DeepSeek all-in-one machine, with its core architecture of "Lenovo server/workstation + Muxi training and recommendation all-in-one domestic GPU + autonomous algorithm", quickly ignites the market enthusiasm. This solution covers mainstream user scenarios, and its heterogeneous computing architecture can support scenarios that require large-scale data processing, comprehensively covering four development scenarios of model inference, model training, knowledge base management, and intelligent entity development, as well as six user application scenarios such as smart office, code development, customer service, document writing, video generation, and intelligent entity training. Since the launch of DeepSeek all-in-one machine, the demand for local deployment of large models in various industries has continued to rise. In the education field, the all-in-one machine has built an immersive practical training platform for teachers and students at Tsinghua University, as well as provided support for the development of artificial intelligence general courses. In the medical field, Wuhan Union Hospital has applied the out-of-the-box DeepSeek AI workstation to personalized medical care, health management, and medical quality control through local deployment, providing decision support for doctors and optimizing patient service processes. In the financial field, relying on DIGIHUMAN, intelligent question-answering systems, and OCR text recognition technology, this product can achieve business process intelligence, significantly improving service response speed and data processing efficiency; government systems can achieve document processing automation, decision intelligence, governance data, and promote grassroots governance modernization; the manufacturing industry uses its reasoning ability to accurately predict equipment failure probabilities, recommend equipment maintenance strategies, and achieve "predictive maintenance." In addition, DeepSeek also shows wide application potential in customer service, creative design, and other fields, becoming an important technical support for industry intelligence upgrade. Rise of domestic computing power ecosystem, leading the industry in full-blooded performance In the context of the reshaping of the global technology competition landscape, the release of the DeepSeek all-in-one machine solution clearly outlines the complete path from technological breakthroughs to commercial landing of the domestic computing power ecosystem. DeepSeek all-in-one machine has quickly gained widespread attention, benefiting from customers' deep trust in Lenovo and Muxi, as well as the long-term technical accumulation of both parties in the domestic computing power base field. The all-in-one machine paired with Muxi's Xisi N260 domestic GPU can support various parameter distillation models of DeepSeek for local deployment. Test data shows that under the same concurrent conditions, the inference performance of the DeepSeek-R1-Distill-Qwen-14B model reaches 110%-130% of the international mainstream GPU. The flagship DeepSeek training and recommendation all-in-one machine, based on Lenovo Wenti WA5480 G3 AI server with Xiyun C500 domestic GPU, achieves performance comparable to international levels. For models up to 671B targeted at users with 4K context in real usage scenarios, the total throughput reaches 1575.4 tokens/s with 64 concurrency, and the actual throughput per user reaches 24.6 tokens/s. In the extreme test with 1024 concurrent users, the maximum throughput reaches 3725.1 tokens/s. Muxi and Lenovo's technical teams continue to push the performance limits through compiler optimization, tensor/data parallelism, MLA, FuseMoE, and other technologies. Based on deep insights into customer needs, Lenovo not only reduces the entry threshold for large model businesses to five thousand yuan, but also can complete deployments in a few hours to achieve true AI inclusiveness. With outstanding service capabilities and strong delivery capabilities, Lenovo has delivered over a thousand all-in-one AI machines pre-installed with DeepSeek in just one month under the wave of new AI technologies, fully demonstrating its rapid responsiveness and landing capabilities. These technological and product innovations are continuously transforming into real business value. Among the shipped devices, models that support local inference of the full-blooded DeepSeek R1 have become mainstream, demonstrating leading advantages in terms of performance and stability. Customer recognition of domestic computing solutions has driven rapid sales growth, injecting strong momentum into the domestic computing power ecosystem. From Muxi's domestic GPU to Lenovo Wenti servers, from domestic large models to self-developed intelligent entity management platforms, the domestic large model computing power ecosystem is gradually taking shape. Accelerating industrial landing, DeepSeek all-in-one machine gains wide trust DeepSeek all-in-one machine has been successfully used in many industries, winning widespread customer recognition with its outstanding performance and stability. In the medical industry, the person in charge of Aier Eye Hospital Group gave high praise: "This cooperation with Lenovo AI all-in-one machine marks a key leap from technical validation to deep scenario applications for AI large models. With our deep accumulation of ophthalmic professional data, we have successfully adopted the DeepSeek large model locally deployed by Lenovo AI all-in-one machine to key aspects such as patient service, medical management, and clinical diagnosis and treatment." Customers in the research field also highly praised it. The head of Xiangjiang Laboratory said: "DeepSeek all-in-one machine provides Xiangjiang Laboratory researchers with powerful computing power support and a stable operating environment for large model applications, which strongly promotes the efficient development of artificial intelligence-related research projects and assists in the high-quality development of Hunan's industrial clusters." Last year, Lenovo and Tsinghua University collaborated.iCenter of the university collaborates to jointly create AI training classrooms and related courses. In response to this, Zhou Jin, Director of the iCenter Research Office at Tsinghua University, said: "In the era of rapid development of artificial intelligence, Lenovo has not only made far-sighted strategic plans, but also has sufficient technical reserves. Our cooperation with Lenovo is a very successful practice."With the successful landing of more and more industry-level applications, the core value of the DeepSeek all-in-one machine is becoming more prominent, and it also points the direction for the future cooperation between Lenovo and Muxi. Both parties will continue to accelerate the industrialization of large model-related technologies and products, leading the intelligent upgrade in a wider range of application fields. Wang Liping, Vice President of LENOVO GROUP and General Manager of China Enterprise Business Group, said: "We believe that the value of AI lies not only in cutting-edge research and development, but also in enabling all industries to easily apply it. Through domestically-produced computing power platforms like the DeepSeek all-in-one machine, Lenovo is committed to promoting the popularization of AI with lower thresholds and higher efficiency, helping various industries quickly enter the era of intelligence." Lv Jun, Executive Vice President of Muxi, also emphasized: "The successful launch of the DeepSeek all-in-one machine fully demonstrates our forward-looking layout and practical capabilities in the field of domestically-produced computing power and AI technology innovation. We will work hand in hand with Lenovo to continue to deepen the core technology of domestically-produced computing power and jointly build a more perfect domestically-produced AI ecosystem. In the future, the DeepSeek all-in-one machine will not only provide efficient intelligent services for more industries, but also inject new energy into the rapid development of China's digital economy, helping customers seize opportunities in the wave of digital transformation." The hot sales of the DeepSeek all-in-one machine not only represent a major breakthrough in the localization of Chinese AI infrastructure, but also signify the initial formation of a "technology-scene-ecosystem" virtuous cycle. Against the backdrop of the accelerating implementation of the "artificial intelligence+" action, this intelligent revolution led by local enterprises is providing a new "Chinese paradigm" for industrial upgrading.

2 h ago

The Hong Kong Stock Exchange condemns FANTASIA (01777), COLOUR LIFE (01778), and nine directors.

Today, the Hong Kong Stock Exchange Limited issued a statement condemning Fantasia Holdings Group Limited (01777) and Colour Life Services Group Limited (01778) for making statements and condemnations against their former chairman, CEO, and executive director, Mr. Pan Jun, and eight other directors for harming investor rights. These companies sold Neighbourhood Joy without the knowledge of shareholders and without obtaining shareholder approval as required by the Listing Rules. Mr. Pan admitted that both the negotiation and execution of the loan, as well as the decision for Colour Life to default on the loan, were solely his actions. He disregarded the internal control policies of the companies, resulting in a violation of the Listing Rules. The Hong Kong Stock Exchange Limited condemns: 1. Fantasia Holdings Group Limited (01777); 2. Colour Life Services Group Limited (01778); And issues statements and condemnations against the following individuals for harming investor rights: 3. Former chairman, CEO, and executive director of Fantasia Holdings and Colour Life, Mr. Pan Jun; Condemning: 4. Former executive director of Fantasia Holdings and Colour Life, Mr. Chen Xinyu; 5. Former non-executive director and former executive director of Fantasia Holdings, Ms. Zeng Baobao; 6. Former executive director of Fantasia Holdings, Mr. Ke Kesheng; 7. Former executive director of Fantasia Holdings, Mr. Zhang Huiming; 8. Independent non-executive director of Fantasia Holdings, Mr. Guo Shaomu; 9. Former non-executive director of Colour Life, Mr. Wu Qingbin; 10. Former independent non-executive director of Colour Life, Mr. Xu Xinmin; 11. Former independent non-executive director of Colour Life, Mr. Zhu Wuxiang; And further instructs: All of the above directors, except Mr. Pan, must undergo training. This case involves Fantasia Holdings and Colour Life evading several provisions of the Listing Rules in a very significant sale transaction. In order to alleviate the imminent liquidity problem, these companies planned to sell their subsidiary, Neighbourhood Joy. Two days after signing a share transfer agreement with the buyer of Neighbourhood Joy, Colour Life entered into a short-term (four days) loan agreement with the buyer, using its equity in Neighbourhood Joy as collateral for the loan. Colour Life failed to repay the loan on time. The buyer exercised their rights under the loan agreement to require Colour Life to transfer Neighbourhood Joy to them. In reality, these companies sold Neighbourhood Joy without the knowledge of shareholders and without obtaining shareholder approval as required by the Listing Rules. The other directors only learned about the loan and the forced transfer of Neighbourhood Joy shortly after the sale. While some members of the Fantasia Holdings and Colour Life board (not involved in this disciplinary action) had expressed concerns, the condemned directors did not question Mr. Pan about the transaction or the compliance of the companies with the Listing Rules, as they believed (including) that the companies needed urgent financing at the time. They also did not question Mr. Pan's actions, including his concealment of the loan agreement and disregard for applicable internal control policies.

06/03/2025

JD HEALTH(06618) daily online consultation volume exceeding 490,000, taking the lead in achieving a closed loop of "medical + examination + diagnosis + medication"

On March 6th, JD HEALTH (06618) released its annual performance announcement for 2024. The announcement showed that JD HEALTH's total revenue in 2024 was 58.2 billion RMB, with a non-IFRS net profit of 4.79 billion RMB, both exceeding market expectations. Among them, the daily online consultation volume of JD Internet Hospital has exceeded 490,000, further consolidating its position as the "first entrance of Internet healthcare." In 2024, JD HEALTH continued to focus on user health, leading the way in connecting online consultation, home testing, doctor diagnostics, and drug delivery services in a closed loop, promoting the iterative upgrade of specialist services, video consultations, and other services. At the same time, it strengthened the construction of internet medical specialties such as mental health and dermatology. Services like "JD Express Testing" and "JD Nurses at Home" continue to expand, continuously leading innovation in medical and health service models.

06/03/2025

Technology leads to cost reduction, efficiency improvement, and increased revenue! JD Logistics (02618) is expected to achieve a total revenue of 182.8 billion yuan and a adjusted net profit of 7.9 billion yuan in 2024.

On March 6, JD LOGISTICS Limited Company (stock abbreviation "JD LOGISTICS", stock code: 02618) released its annual performance report for 2024. In 2024, JD LOGISTICS achieved a revenue of 182.8 billion RMB, a year-on-year increase of 9.7%, with a revenue of 52.1 billion RMB in the fourth quarter, a year-on-year increase of 10.4%. Among them, the revenue from external customers in 2024 reached 127.8 billion RMB, a year-on-year increase of 9.6%, accounting for nearly 70% of total revenue, serving over 80,000 external integrated supply chain customers. It is worth mentioning that in 2024, JD LOGISTICS has consistently adhered to the operational philosophy of "placing goods closest to consumers, reducing handling times and distances", promoting the construction of supply chain infrastructure, technological advancement, and innovative models. Through meticulous operation and management, JD LOGISTICS has further improved its operational efficiency, achieving a new record in profitability. In 2024, JD LOGISTICS' adjusted net profit reached 7.9 billion RMB, a year-on-year increase of 186.8%. Technological and model innovation drives performance growth Over the years, JD LOGISTICS has always placed technological innovation at the forefront, focusing on the organic integration of innovative technological services with diverse scenarios. By exploring cutting-edge technologies and developing logistics technology products and solutions that are digitalized, intelligent, and integrated, JD LOGISTICS has effectively promoted cost reduction, efficiency enhancement, and industry upgrading. Currently, JD LOGISTICS' technology-driven products and solutions cover the main processes and key links in the logistics supply chain, creating a logistics technology hardware and software product matrix that spans the entire supply chain. Through key technologies such as digital twins and artificial intelligence, JD LOGISTICS has established comprehensive technology service capabilities that cover all scenarios of the supply chain. In 2024, JD LOGISTICS further upgraded its digital supply chain technology landscape with the introduction of the "JD LOGISTICS Super Brain", integrating AI, big data, operations research, and other digital technologies deeply into various logistics processes. This focuses on cost reduction and efficiency enhancement throughout the supply chain, achieving intelligent applications from planning to warehousing, distribution, and delivery scenarios. The "JD LOGISTICS Super Brain" integrates advanced technologies and software and hardware collaboration, achieving comprehensive intelligence in scenarios such as storage, picking, packaging, and sorting. The "JD LOGISTICS Super Brain" system, based on self-developed distributed simulation technology, has the ability to simulate millions of orders and process millions of data in minutes, integrating algorithms such as volume prediction, dynamic routing, and intelligent scheduling to dynamically adjust transport resources and optimize transport routes. The logistics large model is also applied in dozens of scenarios such as anomaly control, process automation, and intelligent interaction, continuously improving front-end identification and prevention of anomalies, enhancing human efficiency, and empowering hundreds of thousands of front-line employees.JD LOGISTICS continues to collaborate with Deppon and Kuayue to refine express delivery solutions, drive sustainable business growth, and currently leads the national fast delivery business including Deppon and Kuayue. By 2024, JD LOGISTICS will further expand its market in core industrial clusters across the country, such as in a well-known furniture professional market. By investing in facilities, straightening routes, and upgrading systems, it has improved operational capabilities, significantly enhanced product competitiveness and service capabilities, and provided efficient and safe transportation services to over 300 local businesses.Integration of external supply chain customers exceeds 80,000 Over the past year, JD LOGISTICS has continued to deepen its industry-specific supply chain logistics service capabilities, further enhancing its customer service capabilities in multiple segments such as home appliances and furniture, fast-moving consumer goods, and more. Currently, JD LOGISTICS can provide home appliance products with recycling quality inspection and both forward and reverse integration services. In 2024, it provided reverse quality inspection refurbishment and nearby warehouse shelving solutions to a leading Chinese small home appliance brand, effectively reducing the customer's handling distance and the number of handling trips by 4 times. In the fast-moving consumer goods industry, as the first Chinese supply chain logistics partner of a well-known international consumer goods brand, JD LOGISTICS not only further undertakes all of its supply chain operations in China, but also successfully expands the omnichannel "one-pallet" cooperation model. The integrated service of "BC multi-scenario, all categories same warehouse" effectively helps customers achieve cost reduction, efficiency enhancement, and positive business growth. With its industry-leading and efficient integrated supply chain logistics services, JD LOGISTICS' high-quality services have basically covered mainstream e-commerce platforms in China by 2024. Currently, JD LOGISTICS operates over 3,600 self-operated warehouses and cloud warehouses nationwide, with a total management area exceeding 32 million square meters. The storage network covers almost all counties and districts nationwide, and on this basis, JD LOGISTICS further explores industry-specific and customized warehousing supply chains. Continued rapid growth in overseas business While consolidating its leading position in domestic services in China, JD LOGISTICS actively expands its overseas business, achieving sustained rapid growth in integrated overseas supply chain revenue in 2024. By the end of 2024, JD LOGISTICS had more than 100 bonded warehouses, direct mail warehouses, and overseas warehouses, with a total management area exceeding 1 million square meters, covering 19 countries and regions globally. In 2024, JD LOGISTICS successfully served a Chinese automobile brand, Shanxi Guoxin Energy Corporation, in central Europe with trunk transportation and warehousing and distribution services. At the same time, JD LOGISTICS also provided end-to-end services covering cross-border transportation, customs clearance, warehousing, and distribution for another Chinese automotive brand entering overseas markets. In the Middle East region, it established the first benchmark warehouse for auto parts, realizing an integrated service of "sea to warehouse + comprehensive distribution in the Middle East" to provide efficient logistics support for Chinese auto brands expanding overseas markets. In addition, in 2024, JD LOGISTICS continued to expand high-quality logistics warehouses in countries like the United States, Japan, Malaysia, and regions like Hong Kong, China, forming a more complete global supply chain logistics coverage capability. Furthermore, JD LOGISTICS continued to expand its cross-border transportation service capabilities, adding multiple international all-cargo airline routes such as Shenzhen to Kuala Lumpur and Ezhou to Bangkok, further enhancing the air cargo transportation connection between China and Southeast Asia. To help Chinese outbound enterprises, cross-border merchants, and overseas companies achieve cost reduction, efficiency enhancement, and high-quality development, JD LOGISTICS will comprehensively promote the construction of a global warehouse network, aviation network, and international express service capabilities, creating a "2-3 day delivery" time efficient circle for overseas warehouses, and dedicated to providing customers with worry-free and efficient global "one-pallet" services. Promoting high-quality employment and practicing social responsibility Over the years, the JD Group has always adhered to the business values of "success through righteousness", and JD LOGISTICS has continuously assumed social responsibilities, fully guaranteeing the wages and benefits of workers, and practicing green and sustainable development concepts. As the only privately-owned enterprise in the industry that has signed formal labor contracts and continuously pays "five social insurances and one housing fund" for all frontline employees, JD LOGISTICS strives to ensure that all employees can have "sufficient retirement support, medical care when needed, and compensation for injuries". By the end of 2024, over 1,200 frontline employees had retired honorably from JD LOGISTICS. At the same time, with its flexible and resilient integrated supply chain capabilities, JD LOGISTICS has responded to natural disasters on multiple occasions, helping disaster-affected populations and regions through frontline efforts. Faced with multiple natural disasters in 2024, JD LOGISTICS quickly initiated emergency rescue operations, coordinated transportation fleets, and urgently transferred supplies from nearby warehouses to deliver them in the fastest possible time. In addition, JD LOGISTICS continues to explore green technology and has created an industry-leading logistics supply chain green development model through AI algorithm efficiency enhancement, the use of green energy and transportation equipment, and the recycling of packaging materials. In 2024, JD LOGISTICS' independently developed MRV-T (carbon footprint monitoring, reporting, verification, and tracking) digital carbon reduction technology was included in the "Green Technology Promotion Catalog (2024 Edition)" published by the National Development and Reform Commission and other departments, becoming the only green technology selected in the logistics green industry category. In addition, JD LOGISTICS' algorithm-based deep integration solution for railway transportation was successfully included in the first batch of typical cases effectively reducing the total social logistics costs released by the National Development and Reform Commission, becoming a benchmark for reducing costs and enhancing efficiency in the logistics industry. Over the years, JD LOGISTICS' ESG achievements have been recognized multiple times by international authoritative institutions. In 2024, JD LOGISTICS' score in the S&P Global Corporate Sustainability Assessment improved, ranking among the top in the global industry, and has recently been included in the S&P Global "Sustainability Yearbook 2025". Hu Wei, JD LOGISTICS CEO and member of the JD Group SEC, stated that thanks to JD LOGISTICS' continuous promotion of technology and innovation over the years, its global supply chain logistics network, spanning the globe, continues to generate economies of scale, driving performance to achieve high-quality growth once again. For many years, JD LOGISTICS has adhered to technology-driven operations, continuously explored the application of cutting-edge technology in logistics supply chains, improved integrated supply chain logistics services and innovation models, tirelessly fine-tuned its express services to perfection, which has been instrumental in supporting JD LOGISTICS.S's own high-quality growth further helps enterprise customers and industries achieve improved quality, increased efficiency, and reduced costs, making a greater contribution to the continuous reduction of logistics costs in the entire society.Formattare il testo significa dare una forma definita e ordinata al testo scritto.

06/03/2025

JD HEALTH (06618) to surpass market expectations in performance for 2024, with total annual revenue reaching 58.2 billion yuan.

On March 6, JD HEALTH Limited (stock code "JD HEALTH", stock codes: 06618 [HKD counter] and 86618 [RMB counter]) released its annual performance announcement for 2024. In 2024, JD HEALTH's total revenue reached 58.2 billion RMB, and its net profit under Non-IFRS standards reached 4.79 billion RMB, exceeding market expectations. As of December 31, 2024, JD HEALTH had over 183 million active users in the past 12 months; the number of third-party partner merchants exceeded 100,000, and the platform ecosystem continued to improve. The daily average online consultation volume of JD Health's Internet hospital has exceeded 490,000. As a leading new type of medical and health service enterprise, JD HEALTH has always adhered to the strategic positioning of "core supply chain of pharmaceutical and health products, medical services as the focus, and digital-driven comprehensive and scenario-based health management enterprise." actively responded to national policies and regulatory guidance, and continuously built an integrated service system. SEC Commissioner of JD Group and CEO of JD HEALTH, Jin Enlin, stated, "In 2024, JD HEALTH has made several innovative breakthroughs in the fields of health product retail and medical health services, with the continuous amplification of social and industry value effects. We will actively fulfill corporate social responsibility, strive to create sustainable value for shareholders and society, and achieve long-term high-quality development." Strengthening pharmaceutical and health supply chain capabilities, comprehensive and deep layout of all-channel business In 2024, JD HEALTH continued to strengthen its advantages in self-operation, enhance the competitiveness of online platforms and instant retail businesses, achieve complementary advantages of three business models, and further open up the ecosystem to achieve high-quality growth with industry chain partners. In 2024, JD HEALTH continued to expand its advantage in self-operation, deepen cooperation with pharmaceutical companies and health product suppliers, continuously improve supply chain efficiency, provide users with a richer range of products and better services, and maintain its leading position in core categories of drugs. In terms of drug retail, based on the continuous enrichment of drug supply, JD HEALTH has assisted in brand innovation and digital upgrades, promoting industry transformation and high-quality development. During this process, JD HEALTH continues to consolidate its advantage as the "first station for new special drugs on the entire network." Through mature initial public offering solutions, help pharmaceutical companies accelerate the full-channel expansion of new drugs and provide patients with cutting-edge treatment options synchronized with the global. In the field of nutrition and health, JD HEALTH deepened cooperation with brand partners, actively expanded segmented category markets, and achieved mutual growth with partners. At the same time, JD HEALTH also published category standard systems for "JD Good Nutrition" and "JD Good Nutrition," actively accelerating the standardization and regularization of the entire category of nutritional health industry. In terms of category breakthroughs, JD HEALTH continues to strengthen the advantages of household medical equipment appliances represented by smart monitoring and respiratory oxygenation, and uses the elderly care scene as a breakthrough to further consolidate its leading position in the industry. In 2024, JD HEALTH served as the venue for the age-old consumer coupons in 19 regions such as Sichuan Province, Guangdong Province, and Henan Province, fully meeting the diverse health needs of the elderly. In the past year, JD HEALTH has increased support for platform merchants, strengthened the synergistic effect between online platform business and self-operated business, and improved the health consumption experience of users. As of December 31, 2024, the number of third-party merchants exceeded 100,000, and the platform ecosystem continued to improve. In 2024, JD HEALTH further strengthened its instant retail business, accelerating the innovation layout of all-channel businesses. As of December 31, 2024, "JD Buy Medicine and Send in Seconds" has successively opened "Online Purchase of Medicine and Medical Insurance Individual Account Payment" services in 18 cities such as Shanghai, Beijing, Guangzhou, Shenzhen, Foshan, Chengdu, Zhengzhou, Shenyang, and Tianjin, and connected to more than 3,000 national medical insurance designated pharmacies, covering more than 100 million people. In addition, JD HEALTH has opened several new types of Jingdong pharmacies in Beijing, creating a new offline pharmacy consumption and service experience; and launched the first self-service drug sales and pick-up machine in Haidian District, Beijing, to more efficiently meet the local residents' medication needs. Connecting the service loop of "Medicine + Inspection + Diagnosis + Medicine," accelerating the integration of Wuxi Online Offline Communication Information Technology Co., Ltd. service formats In 2024, JD HEALTH persisted in focusing on user health, promoting innovation in medical and health service models, further perfecting the internet medical service loop, upgrading the experience of at-home services, and meeting users' multi-level health needs. As of December 31, 2024, the daily average online consultation volume of the JD Internet Hospital exceeded 490,000. Over the past year, the JD Internet Hospital continued to consolidate its advantages in internet medical services, leading the industry, and achieving a service loop of "Medicine + Inspection + Diagnosis + Medicine." From online consultation with doctors and doorstep sample collection testing, to doctor diagnosis and prescription and medication delivery to home, the complete process of seeing a doctor and buying medicine can be efficiently completed in the service format centered around the JD Internet Hospital. At the same time, JD HEALTH continued to strengthen the construction of internet medical specialty capabilities. In the field of mental health specialties, JD HEALTH initiated the project of "Automatic Assisted Medical Record Generation System based on multi-modal large model AI technology" with Wuhan University People's Hospital, to improve the efficiency and accuracy of outpatient services in psychiatry through technological innovation. JD HEALTH also cooperated with Shanghai Mental Health Center, Peking University Sixth Hospital, Xiangya Hospital of Central South University, and Wuhan Mental Health Center and other leading domestic institutions in mental health specialties, to jointly begin a.Launch a series of popular science education projects to accelerate the public's deep understanding of digital mental health services. In the field of dermatology, JD HEALTH has invited over 120 doctors and experts and more than 6000 patients to carry out a skin AI patient management project, jointly exploring the innovative applications of large-scale model technology in assisting diagnosis, customizing diagnosis and treatment plans, post-diagnosis follow-up, etc. Currently, the large-scale application of AI in dermatology has been implemented, with an accuracy rate of over 95% in AI multimodal diagnosis.JD HEALTH is actively expanding the number of projects and geographical coverage of the "JD Daojia Quick Testing" service, launching 149 home testing service products for users in 12 cities, providing users with offline medical institution-level testing and inspection services. In the past year, the "JD Nurse at Home" service has also launched nearly 40 home medical care projects, where users can order services online and have licensed nurses provide professional medical care services such as blood collection, wound dressing, and injections at their homes. Promoting the large-scale application of medical models and landing in all scenarios to help medical inclusion with technology By 2024, JD HEALTH will further accelerate the application of large-scale model technology in various service scenarios, aiming to provide users with a more professional, convenient, and safe integrated medical health service experience. As of now, JD HEALTH is the first internet medical platform to scale up and land large-scale model applications in the industry, dedicated to making patients' medical visits more comfortable, doctors' clinical research more efficient, and hospitals' overall operations easier. Over the past year, JD HEALTH has released smart health assistants such as "Kangkang," AI mental health companion products like "Chatting Universe," mobile blood pressure testing services, and more, aiming to build an online medical service ecosystem entrance. For medical professionals, JD HEALTH has created the "Smart Doctor Assistant," providing functions such as clinical decision support, intelligent patient management, and clinical research assistance, which has become the most widely used and adopted intelligent diagnosis tool by doctors. In hospital settings, JD HEALTH has upgraded the intelligentization of the hospital's outpatient process to bring a more convenient experience to patients seeking medical care; among them, the new generation smart hospital service product jointly built by JD HEALTH and the First Affiliated Hospital of Wenzhou Medical University has begun to be widely promoted and implemented. Fully leveraging its own advantages and actively taking on corporate social responsibility By 2024, JD HEALTH will fully leverage its supply chain, medical services, and other advantages to steadily advance the operation of rare diseases, medical social work public welfare projects, and initiate innovative public welfare projects such as children's mental health and expired drug recycling. The "JD HEALTH Rare Disease Care Plan" has been launched for three years, providing assistance to 637 patients, with funds and material value exceeding 6 million RMB. The "Yi Xin Yi Zhan" medical social work public welfare project initiated by JD HEALTH, in cooperation with the Peking Union Medical College Hospital Rare Diseases Outpatient Clinic, Peking University First Hospital Neurology Department, and Children's Medical Center, has provided medical support to more than 20,000 patients. JD HEALTH has also initiated the "Expired Drug Recycling Public Welfare Project," with over 57,000 users participating nationwide, collecting a total weight of 11 tons of medications, generating a wide-ranging social impact. The "Growing Hearts and Minds" children's mental health protection campaign initiated by JD HEALTH has introduced professional mental health services into primary and secondary schools, establishing cooperation with multiple schools in Beijing, Xinjiang, Jilin, and benefiting nearly ten thousand teachers and students. In the future, JD HEALTH will continue to consolidate its advantages in retail pharmacies, fully leverage its self-operated and online platforms, as well as synergize its eco-system between offline and online channels, continuously strengthen its leading position in the industry's comprehensive, all-channel pharmaceutical health supply chain system, further build trust with brands and merchant partners, improve the accessibility and user experience of pharmaceutical and health products across all channels, and maintain the leading market share in core categories such as medications. JD HEALTH will also continue to drive innovation in medical health service models, aiming to connect more medical health service institutions and a wider range of resources such as doctors, pharmacists, nutritionists, etc., continually improve the integrated medical health service system. JD HEALTH is also committed to applying digital and intelligent means to a wider range of users, doctors, and partners, driving the accelerated implementation of inclusive healthcare through technological innovation. JD HEALTH will always adhere to the operating philosophy of "worthy of trust, with the user's health at the center of value creation," closely cooperating with ecosystem partners to jointly improve the integrated new medical health service ecosystem and promote development with consumers, industry, partners, society, and the environment.

06/03/2025

Vertex Pharmaceuticals (01952) announces the first patient dosing of the novel mRNA personalized cancer treatment vaccine EVM16 developed independently.

On March 6th, China New Shine (01952) announced that its independently developed novel mRNA personalized tumor therapeutic vaccine EVM16 has successfully completed the first patient dosing at Peking University Cancer Hospital, marking a milestone in this clinical trial project. The clinical trial project EVM16CX01 is the first human trial conducted by EVM16, initiated by Peking University Cancer Hospital and Fudan University Affiliated Cancer Hospital, to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection monotherapy and combination with PD-1 antibody therapy in late-stage or recurrent solid tumor subjects in a dose escalation and expansion study. EVM16 is a novel mRNA personalized tumor therapeutic vaccine developed by China New Shine, driven by AI algorithms to identify tumor neoantigens. Using the independently developed and self-iterative EVER-NEO-1 "Miao Suan" tumor neoantigen artificial intelligence AI algorithm system, which recognizes tumor neoantigens with high immunogenicity based on each patient's unique tumor cell mutations, and designs mRNA therapeutic vaccines encoding dozens of tumor neoantigens. EVM16 efficiently delivers antigens in vivo through lipid nanoparticle (LNP) delivery system, activating the patient's own neoantigen-specific T cell immunity, thereby achieving the goal of killing tumor cells and treating cancer. In preclinical studies, EVM16 has elicited strong neoantigen-specific T cell immune responses in various mouse models and achieved significant tumor growth inhibition in a mouse melanoma B16F10 model. China New Shine's EVER-NEO-1 "Miao Suan" tumor neoantigen artificial intelligence AI algorithm system not only identifies the majority of reported tumor neoantigens, but also identifies multiple previously unreported tumor neoantigens, demonstrating comparable or superior neoantigen prediction capabilities in multiple independent validation studies compared to industry-leading algorithms. Preclinical data also demonstrate that EVM16 has a synergistic anti-tumor effect when used in combination with PD-1 antibodies, supporting the combination of personalized tumor vaccines with immune checkpoint inhibitors in clinical practice. In preclinical safety evaluation trials, EVM16 also demonstrated good safety. These results collectively suggest that EVM16 injection immunogenicity is strong, safety is good, and the combination with immune checkpoint inhibitors is expected to bring more clinical benefits to cancer patients. Professor Shen Lin, Director of the Department of Digestive Tumors at Peking University Cancer Hospital and Chairman of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology, said, "Our team is very pleased to have completed the first patient dosing of the personalized tumor vaccine EVM16, which marks a new phase in the clinical research of EVM16. EVM16 uses mRNA technology to 'tailor' anti-cancer solutions for patients based on the specific mutations or epitopes of each patient's tumor, activating the patient's own tumor-specific immune response and then recognizing and attacking tumor cells. Particularly encouraging, in preclinical studies, the combination of EVM16 vaccine with PD-1 antibody showed a significant synergistic anti-tumor effect, demonstrating broader clinical application prospects, indicating that EVM16 is expected to provide a more diverse treatment strategy. We are confident in the following studies and look forward to providing new and accessible treatment options for cancer patients, bringing hope of life to patients worldwide." China New Shine CEO Luo Yongqing said, "In recent years, AI-empowered new drug development has become an important trend, especially in the mRNA vaccine field, where AI is gradually becoming a key force driving the improvement of R&D efficiency and accuracy, receiving high attention from the biopharmaceutical industry and strong support from governments around the world. Since 2021, China New Shine's mRNA platform has successfully passed clinical verification, and the company is committed to the independent development of tumor therapeutic vaccines, using AI algorithms to discover tumor neoantigens, continuously optimizing the algorithm platform for more precise identification and validation of tumor neoantigens, laying the foundation and leading advantages for the self-developed mRNA therapeutic tumor vaccines. As the first personalized mRNA therapeutic tumor vaccine independently developed by China New Shine, the successful dosing of the first patient with EVM16 marks a solid step from laboratory research to clinical application, demonstrating that China New Shine's proprietary tumor neoantigen AI algorithm system and mRNA technology platform with independent intellectual property rights have successfully entered the human trial stage. Currently, China New Shine has successfully localized its self-developed mRNA platform that has been clinically validated and has built an end-to-end full-industry chain platform covering antigen design, mRNA sequence optimization, LNP delivery technology to industrial production, having the potential to address significant unmet medical needs globally. We look forward to EVM16 demonstrating its therapeutic potential in clinical trials, bringing new treatment options to cancer patients worldwide, improving treatment outcomes, providing more choices for patients with life-threatening tumors, and exploring new blue oceans in tumor immunotherapy." Globocan The 2022 statistics show that there are 19.976 million new cancer cases worldwide, with 9.744 million cancer deaths. Immune therapy, mainly immune checkpoint inhibitors, has become a significant part of certain cancer treatments. Still, it is only effective for some patients, and the oncology field urgently needs to develop novel immune therapies based on this. Personalized mRNA tumor vaccines have become a highly promising next-generation immune therapy. China New Shine is developing tumor and other therapeutic mRNA drugs through its proprietary mRNA technology platform and has full intellectual property rights and global ownership of these products. The company is currently developing multiple mRNA tumor therapeutic vaccines, including Personalized Cancer Therapeutic Vaccine (PCV), Tumor-Associated Antigen (TAA) Tumor Therapeutic Vaccine, Immune Modulating Tumor Therapeutic Vaccine, and Autologous CAR-T Products, and is developing a new generation LNP delivery system to enhance cell-mediated immune responses. The new drug clinical trial of the Tumor-Associated Antigen (TAA) vaccine will be submitted for approval in both China and the United States by 2025.

06/03/2025

After the profit warning, why did Joinn Laboratories (06127) see its stock price rise nearly 90% in just one and a half months by hitching onto the rising Hang Seng Index?

On January 24, Joinn Laboratories (06127) disclosed a profit warning, expecting a year-on-year decrease in net profit attributable to the parent of approximately 77.8% to 85.2% for the 2024 fiscal year. Additionally, Joinn Laboratories also mentioned in the announcement: during the reporting period, the company's laboratories maintained a good operational status, but due to intensified industry competition, increased pressure to secure contracts, declining order prices, and squeezed profit margins, the gross profit margin decreased year-on-year, resulting in a corresponding decrease in net profit from laboratory services. Furthermore, the market prices of biological assets held by the company decreased during the reporting period, leading to a negative impact on performance due to changes in fair value of biological assets. The pressures of securing contracts, squeezed profit margins, and risks of falling prices have not been eliminated. For a CRO company, these challenges alone are enough for the market to "whip up a storm", but Joinn Laboratories has taken a different path. Observing the situation after January 27, Joinn Laboratories' Hong Kong stock price has been steadily climbing, reaching a high of 16.28 Hong Kong dollars during trading on February 27, with a closing price of 15.56 Hong Kong dollars on the same day. The increase in the range was as high as 85.24%, with a growth rate far exceeding the industry average. Despite the lackluster performance, Joinn Laboratories' stock price appears to have deviated from the traditional logic of the CXO industry recovery and entered the realm of asset revaluation. Behind the nearly 90% increase in a month and a half In terms of market sentiment, since Joinn Laboratories saw a significant increase in trading volume of 11.91% on November 4 last year, achieving a daily turnover of 181 million Hong Kong dollars on that day, the internal and external disagreements in the market have converged, with holders tending to wait for gains and not easily give up their holdings. Until February 20, the circulation of the substantial draft opinion on improving the drug pricing mechanism and measures for supporting innovative drugs for high-quality development in the second round of consultations resonated with the Class B Catalog and commercial reimbursement, benefiting the long-term development of high-quality innovative drugs. As a result, the CXOs and innovative drug stocks in both AH markets surged, boosting overall sentiment in the pharmaceutical industry. Looking at the emotional cycle, since January this year, the sentiment towards CXO targets in the Hong Kong stock market has been fluctuating around the freezing point, with internal and external perspectives remaining bearish, leading to low trading volumes. After "together for a long time, must part ways", before February 20, there was a clear increase in trading volume differences within the CXO sector, and the circulation of this important document became the catalyst for the surge in the CXO topic sentiment. It is not difficult to see that on February 20, many CXO targets in the Hong Kong stock market released heavy trading volumes to pull up large positive trends, achieving a long-awaited turnover internally and externally. Except for Asymchem Laboratories, the other CXO companies continued to rise the next day, cashing in on the emotional premium. Generally, market sentiment driven by news speculation rises quickly and falls just as quickly. On February 24 and 25, Pharmaron Beijing and Hangzhou Tigermed Consulting continued to fluctuate and decline. In contrast, Joinn Laboratories saw two days of shrinking trading volumes on the 24th and 25th, accelerating internal agreement, and closing up 3.31% on the 25th, exceeding market expectations. Therefore, it gained market sentiment premium the next day, with the stock price rising by 11.21%, widening the gap with other industry peers. Buying intentions of the southbound funds? At the end of September last year, there was a global wave of revaluation of assets priced in RMB, benefiting the Hong Kong stock market. At the beginning of this year, the emergence of Deepseek ignited the market again, accelerating the revaluation of China's new quality production capacity valuation system globally. The most direct manifestation is the Hang Seng Tech Index, which has risen more than 40% in the past one and a half months since its launch on January 14 this year, leading the entire AH markets out of the early year market boom led by new quality production concepts such as AI, computing power, and humanoid Siasun Robot&Automation. Data shows that in February, the cumulative net purchases of southbound funds in Hong Kong stocks reached 152.8 billion Hong Kong dollars, setting a new monthly high in the past four years and second only to the net purchases of 310.6 billion Hong Kong dollars in January 2021, which is the second largest single-day net purchase in history. In addition, in just two months since 2025, the total net purchases of Hong Kong stocks have reached 278.4 billion Hong Kong dollars, exceeding the full-year net purchases in many previous years. The emotional premium in this round of market rally is also reflected in Joinn Laboratories' Hong Kong stock price. Over the past 60 days, China Creation has been the largest buyer of Joinn Laboratories, with a net purchase of 8.8737 million shares. Furthermore, since the beginning of this year, southbound funds have been increasing their holdings in Joinn Laboratories, with the highest stake reaching 40.24%. The path of increasing holdings by southbound funds seems to show different logics at different points. In the period from the beginning of the year to February 10, southbound funds were "buying more as it fell" for Joinn Laboratories, focusing on low-cost holdings. However, after February 20, southbound funds started to "buy more as it rose" for Joinn Laboratories, showing strong buying intentions. The change in the logic of holdings by southbound funds for Joinn Laboratories may be a reflection of the change in the logic of low-valuation high-quality asset allocation in the Hong Kong stock market. As mentioned earlier, overseas funds are accelerating the acquisition of massive undervalued high-quality assets priced in RMB, and the increase in southbound funds may be a form of "resistance" in the asset allocation landscape. Additionally, for Joinn Laboratories itself, although the company issued an annual profit warning, the content shows a turnaround in net profit attributable to the parent and net profit from laboratory services.Come see, Joinn Laboratories' net profit attributable to shareholders has actually started to decrease from the second quarter of this year, and the latest financial report shows that it has stopped falling and started to rise again. As for the market's concerns about the monkey price losses, they are also narrowing further, indicating that its risks are being cleared.During the overall downturn in the industry, Joinn Laboratories, as a leading company, has shown a stronger resilience against the trend, exceeding market expectations, and obviously presenting a larger margin of safety for investment. In addition to its solid fundamentals, the logic behind the Southbound funds allocation to Joinn Laboratories may also involve "speculation on AI concept". It is understood that in July last year, Joinn Laboratories announced that the digital pathology assistant analysis system developed in cooperation with Shengzhi Intelligence has been widely recognized in practical application. The company also stated that, based on the completion of digital transformation, it will continue to focus on the AI field, introducing comprehensive AI assisted diagnostic technology, expanding the application scenarios of AI technology in the CRO field, and providing intelligent solutions for customers to improve research and development efficiency. It is reported that Joinn Laboratories is currently one of the few CXO leading companies in the AH region that explicitly engage in AI-assisted business, which coincides with the bull market initiated by the Deepseek concept, making it a "AI medical concept stock" on the current hot Hang Seng Technology Index, forming a resonance.

06/03/2025

Monica.im has launched a universal AI Agent "Manus" whose performance surpasses or equals OpenAI.

According to reports, Monica.im officially launched the universal AI Agent product "Manus" developed by its Chinese team globally. Manus achieved SOTA (State-of-the-Art) results in the GAIA benchmark test, surpassing the performance of the same-level large model "Deep Research" by OpenAI. Compared to current large model products, as a universal AI Agent, Manus is positioned as a powerful universal assistant that not only provides ideas to users but also puts those ideas into practice to truly solve problems. From the release demo, Manus can directly operate the computer to complete a series of tasks such as report writing and spreadsheet creation after receiving instructions, and ultimately exports finished products that meet user needs. Unlike various relatively simple AI assistants, Manus has a "digital brain" with strong learning ability and adaptability, no longer limited to single tasks, able to understand complex instructions, autonomously learn, and collaborate across domains, "truly thinking and acting like a human." The team members are from mainland China and plan to open-source some of the technology in the future to promote the common development of the AI community. It is understood that the founder of Monica.im is Red, a post-90s born in mainland China in 1992, and a graduate of Huazhong University of Science and Technology. In 2022, with the rise of large models, Red saw the potential of AI development and founded Monica, focusing on the overseas market. By launching the independent developer product ChatGPT for Google, the product quickly completed a cold start. By 2024, with the launch of GPT-4o, Claude 3.5, and OpenAI o1 series, Monica allows users to access the latest SOTA models. By integrating new model advancements, it launched professional search, DIY Bot, and more. By 2024, its user base reached 10 million, leading among similar products overseas, and maintaining a substantial profit.

06/03/2025

HUITONGDA NET (09878) was awarded the "Annual Excellent ESG Demonstration Enterprise" award.

On March 5th, HUITONGDA NET Limited (09878) joyfully announced that it was awarded the "Annual Excellence ESG Demonstration Enterprise" at the 2025 Global Finance and ESG Sustainable Development Summit and the 2nd Victoria Harbour Overseas Outstanding Institutions Selection, in recognition of its outstanding performance in accelerating the digitalization of rural economies, improving the efficiency of retail stores in underserved markets, and promoting the Shenzhen Agricultural Power Group's transition from villages to cities. The event was jointly organized by the Greater Bay Area Financial Association and Zhongchengxin Green Gold Corporation, with support from the Hong Kong Special Administrative Region Investment Promotion Bureau, aiming to promote sustainable development by bringing together industry elites to share insights and drive progress. Furthermore, in order to recognize outstanding contributions to investment, innovation, and sustainable development, the organizers also held the Victoria Harbour Overseas Outstanding Institutions Selection awards ceremony, where winning companies were selected by a panel of renowned chief economists, representatives from domestic and foreign financial institutions, and other industry experts. HUITONGDA NET has always been committed to its mission of improving the lives of farmers, utilizing its rich data assets to help rural mom-and-pop stores overcome challenges related to weak supply chain and digital capabilities, limited marketing strategies, and lack of customer channels. Through its comprehensive SaaS+AI solution, nearly 130,000 rural mom-and-pop stores nationwide are able to achieve full digital management of inventory, memberships, marketing, and customer service, as well as improve operational efficiency and marketing effectiveness through data sharing and analysis. Furthermore, with its robust online platform, HUITONGDA NET has paved a way out for rural mom-and-pop stores, injecting new vitality into the economic development of farming families and promoting the prosperity of rural economies. In the future, the group will continue to enhance its SaaS+AI platform and digital capabilities, focusing on "supply chain + technology + service" as core barriers, to create greater value for rural mom-and-pop stores and the overall underserved market economy.

06/03/2025

Contact: contact@gmteight.com